[SCHEDULE 13G] Ascendis Pharma A/S Passive Investment Disclosure (>5%)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Ascendis Pharma A/S ownership disclosure: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,162,042 ADRs, equal to 9.9% of the class as reported 03/31/2026. The filing lists sole voting power for 5,884,715 shares and sole dispositive power for 6,162,042 shares.
Positive
- None.
Negative
- None.